Key Positives From The 1Q Results
Revenue reached JPY 950M (+208.3% YoY) and gross profit turned positive at JPY 374M, marking an inflection point in the earnings structure. AxelGlobe drove the improvement. It began recognizing revenue as the Ministry of Defense (MOD) "Satellite Constellation Development and Operation Project" progressed, and segment profit swung to a JPY 234M surplus. The GRUS-3 malfunction triggered an impairment, but the improvement in core profitability is clear in the numbers.
- Gross Margin Recovery: Gross Profit Margin improved to 39.4% (prior year: -5.5%). AxelGlobe gross profit of JPY 856M more than offset AxelLiner's gross loss.
- AxelGlobe Profitable After R&D: The MOD contract, orders from existing customers and progress on METI-commissioned research kept AxelGlobe in the black. This held even after absorbing R&D costs for three high-resolution satellites.
- Narrower Operating Loss: Operating loss narrowed by JPY 236M YoY to JPY -826M. SG&A was contained at JPY 1,201M (+14.8% YoY).
- Healthy GRUS-3 Units Preserve Upside: Of the seven GRUS-3 satellites, the three without defects are targeted for commercial operation from February 2027, preserving a revenue opportunity.
- Covenant Risk Deferred: Under the Mizuho Bank facility, the covenant requiring a profit has been pushed back from FY5/27 to FY5/29 onward. This reduces near-term breach risk.
Key Concerns From The 1Q Results
Four GRUS-3 satellites malfunctioned, and the company booked a JPY 1,879M impairment loss as an extraordinary loss. Net loss widened to JPY -2,784M and net assets fell to JPY 4,244M. The delayed start of imagery delivery and uncertainty over the Pale Blue contract led management to cut the full-year revenue plan by 25.6% from the previous forecast. The filing also flags events or conditions that cast significant doubt on the company's ability to continue as a going concern. Funding stability is therefore the key issue.
- AxelLiner Revenue Reversal: After receiving a contract termination notice from Pale Blue, the company reversed revenue. AxelLiner booked negative revenue of JPY -63M, and segment loss widened to JPY -615M.
- New Loss Provision: A new JPY 68M provision for project losses confirms AxelLiner's deteriorating profitability.
- Shrinking Cash Cushion: Cash and deposits fell JPY 2,413M from the prior fiscal year-end to JPY 3,402M. Headroom is narrowing against the SMBC covenant requiring cash of at least JPY 2B at each quarter-end.
- Rising Advance Payments: Advance payments rose to JPY 4,013M (+JPY 849M). Satellite launches and component orders continue to tie up cash.
- Lower Equity Ratio, Dilution Risk: The equity ratio fell to 37.7% (-10.0pt vs. prior year-end). The stock acquisition rights with an exercise price adjustment clause, announced the same day, are dilutive.
Focus Areas / Items To Monitor Going Forward
- Commercial Launch Of Healthy Units: Whether the three healthy satellites start commercial operation on schedule in February 2027. The AxelGlobe full-year revenue plan of JPY 4,240M assumes a ramp-up in GRUS-3 imagery delivery on top of the MOD contract.
- Pale Blue Outcome And AxelLiner Recovery: The outcome of talks with Pale Blue and AxelLiner's earnings recovery, anchored by NEDO-commissioned research. AxelLiner has already used 49.6% of its full-year segment loss budget of JPY -1,240M in 1Q (our estimate).
- Warrant Exercise And Liquidity: The pace of exercise of the 12th Series Stock Acquisition Rights and the trend in liquidity. Key items are compliance with the JPY 2B cash covenant and access to the JPY 2,939M undrawn credit facility.
- Progress on the GRUS-3 root-cause investigation, and how findings will feed into the design of the three high-resolution satellites slated for launch in FY5/28
- The revenue recognition schedule for the MOD satellite constellation project, and how far the GRUS-3 malfunction affects contract performance
- Expected proceeds from the 12th Series Stock Acquisition Rights, priorities for use of funds and the approach to financial covenants
- The outlook for talks with Pale Blue, and potential upside from the revised plan that reflects the "maximum impact"
- The possibility of recovering losses through satellite insurance, and plans to procure and launch replacement satellites
Key Financial Highlights
| Item | Value | YoY |
|---|---|---|
| Revenue | JPY 950M | +208.3% |
| Total Income (Non-GAAP) | JPY 950M | +208.3% |
| Gross Profit | JPY 374M | Turned positive (prior year: JPY -16M) |
| └ Gross Profit Margin | 39.4% | +44.9pt (our estimate) |
| SG&A | JPY 1,201M | +14.8% |
| Operating Income | JPY -826M | Loss narrowed (prior year: JPY -1,063M) |
| Recurring Profit | JPY -902M | Loss narrowed (prior year: JPY -1,190M) |
| Extraordinary Loss (Impairment Loss) | JPY 1,879M | Prior year: JPY 230M |
| Quarterly Net Income Attributable to Owners of Parent Company | JPY -2,784M | Loss widened (prior year: JPY -1,422M) |
| EPS | JPY -41.78 | Prior year: JPY -29.97 |
| Depreciation | JPY 6M | Prior year: - (not disclosed) |
There was no subsidy income in 1Q, so total income equaled revenue. The operating loss narrowed, but the JPY 1,879M impairment on four GRUS-3 satellites roughly doubled the net loss YoY. The wider EPS loss reflects the larger net loss. The IPO lifted the average share count from 47.47M to 66.66M shares, which limited the increase in the per-share loss.
Performance By Business Segment
AxelGlobe posted a sharp increase in both revenue and profit on the MOD contract, underpinning consolidated results. By contrast, AxelLiner booked negative revenue after reversing revenue on the Pale Blue contract, and its loss widened. Following the March 2026 reorganization, R&D costs for in-house commercial satellites are now booked under AxelGlobe. Prior-year figures have been restated on the new basis.
Segment Performance Table
| Segment | Revenue | YoY | Segment Profit | YoY | Margin |
|---|---|---|---|---|---|
| AxelLiner | JPY -63M | - | JPY -615M | Loss widened (prior year: JPY -450M) | - |
| AxelGlobe | JPY 1,014M | +3,302.2% | JPY 234M | Turned positive (prior year: JPY -287M) | 23.1% |
| Adjustments | - | - | JPY -521M | Prior year: JPY -452M | - |
| Consolidated | JPY 950M | +208.3% | JPY -902M | Loss narrowed (prior year: JPY -1,190M) | -94.9% |
*Segment profit is on a recurring profit basis (company disclosure). Margins are our estimates.
- AxelGlobe (MOD): The "Satellite Constellation Development and Operation Project" won last fiscal year progressed, lifting revenue to JPY 1,014M from JPY 29M a year earlier. The company is participating in a national program worth JPY 283.1B in total over roughly five years. This provides a medium-term revenue base.
- AxelGlobe (Existing Customers / METI-Commissioned Research): Orders from existing customers and progress on METI-commissioned research also contributed, delivering gross profit of JPY 856M. The segment stayed profitable even after absorbing R&D costs for three high-resolution satellites.
- AxelLiner (Pale Blue Contract): The company received a written notice regarding contract termination and opened talks. It reversed revenue given uncertainty over whether the contract will continue, leaving revenue at JPY -63M. Cost of goods sold of JPY 417M (+56.0% YoY) remained, resulting in a gross loss of JPY 481M.
- AxelGlobe (GRUS-3 Satellite Assets): Of the seven satellites launched in July 2026, four developed defects in downloading imagery data via the high-speed communication system. Commercial operation of these units was deemed difficult, and the company booked a JPY 1,879M impairment. Imagery delivery is expected to start later than planned, and the full-year segment revenue plan was cut by 30.3% from the previous forecast.
Progress Versus Full-Year Guidance
Revenue progress stands at 14.2%, slightly ahead of 12.3% in 1Q last year (our estimate). However, hitting the plan requires JPY 5,749M of revenue from 2Q onward. That assumes continued revenue recognition on AxelGlobe's MOD contract and the start of operations for the healthy GRUS-3 satellites. Driven by the one-off impairment, the net loss already reached 76.3% of the full-year plan in 1Q. That leaves room for only JPY -865M of net loss over the remaining three quarters (our estimate). Subsidy income of JPY 1,210M accounts for the gap between the total income and revenue plans. Its timing will determine where recurring profit lands.
| Item | Value (1Q Cumulative) | Full-Year Forecast | Progress Rate |
|---|---|---|---|
| Revenue | JPY 950M | JPY 6,700M | 14.2% |
| Total Income (Non-GAAP) | JPY 950M | JPY 7,910M | 12.0% |
| Operating Income | JPY -826M | JPY -2,300M | 35.9% (loss consumption) |
| Recurring Profit | JPY -902M | JPY -1,700M | 53.1% (loss consumption) |
| Net Income | JPY -2,784M | JPY -3,650M | 76.3% (loss consumption) |
| AxelGlobe Revenue | JPY 1,014M | JPY 4,240M | 23.9% |
| AxelGlobe Segment Profit | JPY 234M | JPY 1,970M | 11.9% |
| AxelLiner Revenue | JPY -63M | JPY 2,460M | - |
| AxelLiner Segment Loss | JPY -615M | JPY -1,240M | 49.6% (loss consumption) |
- Year-End Concentration: Last fiscal year, 4Q standalone revenue of JPY 1,541M accounted for 61.4% of the full-year total, with revenue concentrated at year-end (our estimate). Project progress and the timing of subsidy income make quarterly results highly volatile.
Changes To Guidance
The 1Q earnings release contained no further revisions. Guidance was already cut on October 6, 2026 following the malfunction of four GRUS-3 satellites and the start of talks with Pale Blue. The company says the revised plan reflects the maximum impact that can be estimated at this point.
- Revenue: Previous JPY 9,000M → New JPY 6,700M
- Operating Income: Previous JPY -800M → New JPY -2,300M
- Net Income: Previous JPY -240M → New JPY -3,650M
- Reasons For Revision: Delayed GRUS-3 imagery delivery cut the AxelGlobe revenue plan from JPY 6,080M to JPY 4,240M. The Pale Blue contract cut the AxelLiner revenue plan from JPY 2,920M to JPY 2,460M. The JPY 1,879M impairment widened the net loss by JPY 3,410M.
Commentary On Shareholder Returns
The FY5/27 dividend forecast remains unchanged at JPY 0.00, with no dividend paid. In 1Q, the company drew down JPY 17,906M of capital reserve to offset accumulated deficits. Retained earnings improved from JPY -15,322M to JPY -200M, with no impact on total shareholders' equity.
Financial Position
The impairment and operating loss reduced both net assets and cash. Interest-bearing debt of JPY 4,505M now exceeds cash of JPY 3,402M, leaving a net debt position of JPY 1,103M (our estimate). The filing still flags events or conditions that cast significant doubt on the going concern assumption. Financial stability will hinge on access to the JPY 2,939M undrawn credit facility and progress in raising funds through the stock acquisition rights.
- Key Figures
- Leverage Metrics
| Item | Value | Additional Information |
|---|---|---|
| Cash and Deposits | JPY 3,402M | -41.5% vs. prior year-end |
| Advance Payments | JPY 4,013M | +26.8%; prepayments for launch contracts and component orders |
| Construction in Progress | JPY 1,811M | -45.7%; reflects GRUS-3 impairment |
| Total Assets | JPY 11,165M | -23.6% |
| Shareholders' Equity | JPY 4,207M | -39.7% |
| Interest-Bearing Debt | JPY 4,505M | -14.5% (our estimate) |
| └ Short-Term Borrowings | JPY 118M | Prior year-end: JPY 0M |
| └ Current Portion of Long-Term Borrowings | JPY 1,504M | Prior year-end: JPY 2,007M |
| └ Long-Term Borrowings | JPY 2,882M | Prior year-end: JPY 3,262M |
| EBITDA | JPY -820M | Operating income + depreciation (our estimate) |
| Metric | Value | Notes |
|---|---|---|
| Debt/Equity | 1.07x | Prior year-end: 0.76x (our estimate) |
| Equity Ratio | 37.7% | Prior year-end: 47.7% (company disclosure) |
Disclosures Released Alongside The Earnings Announcement
- 2026/10/15Released supplementary materials for 1Q results (Supplementary Materials for 1Q FY5/27 Financial Results)
- 2026/10/15Announced planned in-orbit demonstration of ASPINA using GRUS-3, outlining a use for the operational satellites (Notice Regarding Planned In-Orbit Demonstration of ASPINA Using "GRUS-3")
- 2026/10/15Changed the management structure of the company and its consolidated subsidiaries; notable as an overhaul of execution following the GRUS-3 malfunction (Notice Regarding Changes to the Management Structure of the Company and Its Consolidated Subsidiaries)
- 2026/10/15Announced recognition of subsidy income as non-operating income, a component of the total income (Non-GAAP) plan (Notice Regarding Recognition of Non-Operating Income (Subsidy Income))
- 2026/10/15Finalized members of the GRUS-3 Malfunction Review Advisory Board, establishing the root-cause investigation framework (Update on Disclosed Matter: Notice Regarding Finalization of Members of the "GRUS-3 Malfunction Review Advisory Board")
- 2026/10/15Issued the 12th Series Stock Acquisition Rights with an exercise price adjustment clause via third-party allotment and entered into a facility agreement, as a measure to secure liquidity (Notice Regarding Issuance of 12th Series Stock Acquisition Rights (With Exercise Price Adjustment Clause) via Third-Party Allotment and Conclusion of Facility Agreement (With Exercise Suspension Clause))
Major Announcements During The Quarter
- 2026/07/17Released first light (first captured images) from next-generation Earth observation satellite GRUS-3
- 2026/09/02Signed a sales agency agreement with Airbus Defence and Space, expanding AxelGlobe's overseas sales channels
- 2026/09/29Four of seven GRUS-3 satellites malfunctioned; commercial operation involving imagery data downloads via the high-speed communication system deemed difficult
- 2026/10/06Cut the full-year revenue plan from JPY 9,000M to JPY 6,700M and booked a JPY 1,879M impairment
- 2026/10/06Received written notice from Pale Blue regarding termination of the in-orbit demonstration service contract and opened talks
Large-Shareholding Filings / Material Proposals Over The Past Year
- SBI Ventures Two (Joint Holders: SBI Ventures Three, SBI Asset Management, SBI Securities): New 5.30% (2026/07/10) → 5.32% (2026/07/16) → 5.08% (2026/07/28) → 4.99% (2026/08/13) → 5.04% (2026/10/02) - Pure investment
- Global Brain: 12.04% → 11.02% (2025/11/14) → 9.26% (2026/03/04) → 8.18% (2026/03/06) → 7.18% (2026/04/16) → 6.14% (2026/04/23) → 5.12% (2026/05/08) → 6.06% (2026/05/13) → 5.01% (2026/05/26) - Pure investment (aimed at capturing returns from the issuer's growth)
- 31VENTURES-Global Brain-Growth I LLC: 8.19% → 7.15% (2025/11/17) → 6.10% (2025/12/03) → 5.08% (2025/12/10) → 3.89% (2025/12/18) - Pure investment; VC fund reducing its stake
- Material Proposals / Shareholder Proposals: None
ENVALITH, INC. ("ENVALITH") provides exclusive research coverage services to domestic and international institutional investors, as well as domestic individual investors, with the objective of contributing to the development of global and Japanese capital markets by providing information necessary for considering investments in Japanese listed companies.
- Purpose and Disclaimer Regarding Investment Decisions
This report has been prepared solely for informational purposes and does not constitute a solicitation to acquire, sell, or hold securities or any other financial products. Furthermore, this report does not constitute specific investment, financial, or tax advice. Any opinions, judgments, or recommendations contained herein are not intended to induce investment activities. Please be advised that all investment decisions must be made based on the investor's own responsibility and judgment, and ENVALITH and subject company shall not be involved in any such investment decisions.
- Information Sources, Accuracy, and Disclaimer of Warranty
This report has been prepared based on a formal request from the subject company, utilizing information provided by and interviews conducted with said company. By using this report, you are deemed to have agreed to the following: 1. Information Sources: This report is prepared on the assumption that the publicly available information and information disclosed by the subject company and provided during interviews is true and reliable. ENVALITH has not independently verified or validated the veracity of such information. 2. Accuracy: The interpretations, analyses, and hypotheses or conclusions based thereon contained in this report are independently derived by ENVALITH using its own perspectives and analytical methods based on the information mentioned in the preceding paragraph. 3. Disclaimer of Warranty: In the event that there are errors or omissions in the information disclosed by the subject company, ENVALITH and subject company shall not be held liable for any inaccuracies in this report resulting therefrom. ENVALITH and subject company make no warranties, whether express or implied, regarding the accuracy, safety, validity, completeness, or any other aspect of this report, nor regarding the past or future performance of the subject company.
- Limitation of Liability
ENVALITH and subject company shall not be liable for any costs, damages, or losses (including direct, indirect, incidental, consequential, or punitive damages) arising from the use of this report or the information obtained therefrom. Users of this report acknowledge and agree that such use is at their own risk.
- Potential Conflicts of Interest
ENVALITH may have, or may have in the future, business relationships with the subject company. Accordingly, investors should be aware that conflicts of interest may exist that could affect the objectivity of this report.
- No Obligation to Change or Update Content
The contents and opinions in this report, as well as the information upon which it is based, are current as of the date of preparation and are subject to change without notice. Please be advised that ENVALITH is under no obligation to update the contents of this report, and investors must verify the timeliness of the information on their own.
- Governing Language
This report is prepared in Japanese, English, and Chinese. In the event of any discrepancy or difference in interpretation between the language versions, the Japanese version shall be treated as the original and shall prevail.
- Copyright
All rights (including copyrights) relating to this report belong to ENVALITH. Any reproduction, redistribution, or other use of all or part of this report without the prior written permission of ENVALITH is strictly prohibited.
- Use for Other Investment Products
Except where ENVALITH has provided prior written approval, the use of this report and the trademarks or trade names of ENVALITH or the subject company in connection with the information distribution, transaction, sales promotion, or advertising of any investment products (including derivatives, structured products, investment trusts, or investment assets whose price, return, or performance is based on or linked to this report) is strictly prohibited.